NOVARTIS
“The latest advancements in automation and AI have dramatically changed the way we work for the better”
Steffen Lang President, Operations Novartis first to commercially scale new types of treatments. Over the past years, Novartis has focused on three advanced platforms which are revolutionising treatments: cell and gene therapies, siRNA therapies and radioligand therapies( RLT), all of which require manufacturing models that are vastly different from conventional tablets or injections. Cell therapy, for example, involves taking cells from a patient, modifying them in a highly controlled facility, then returning the treatment to the same patient a few days later. Gene therapy has also opened a new route to treatment,